Diagnostics Accelerator Portfolio Days

The Diagnostics Accelerator is excited to announce the second event in our Diagnostics Accelerator Portfolio Days series. These semi-annual virtual events for our investor community showcase a selection of Diagnostics Accelerator portfolio companies, providing an opportunity for potential investors to engage with founders and learn more about their exciting contributions to the development of biomarkers for Alzheimer's disease and related dementias.

The second event will feature Optina and Altoida and will be held on November 17th from 9-10am PST (12-1pm EST). Private and institutional investors are welcome to attend. To register for the event, please fill out the following form: DxA Portfolio Days Attendee Interest Form.

DxA PORTFOLIO OVERVIEW

Portfolio

Learn more about the current DxA portfolio and our investment diligence.

PAST PORTFOLIO DAYS

Portfolio

View pitch decks and recordings from our past events.

Altoida Logo

Altoida is creating a cell phone and tablet-based digital biomarker platform for evaluating cognition. This platform can measure brain health in 10 minutes with a battery of immersive augmented reality activities. Through a set of tasks that simulate activities of daily living, Altoida’s cognitive assessment platform aims to detect mild cognitive impairment and subjective cognitive decline in individuals at high Alzheimer’s disease risk. View screener.

Travis Bond
Travis Bond, MBA
Chief Executive Officer, Altoida

Travis Bond, MBA is the Chief Executive Officer of Altoida, a commercial-stage technology company building the leading platform to accelerate and improve drug development, research, and care for people with neurological diseases using AI and multimodal data captured with a standard smartphone or tablet. He is a digital health executive, disruptor, and serial entrepreneur with over 25 years of experience in building and leading healthcare technology and services companies for B2B and B2C markets. The technology platforms, products, and services that his companies have built have impacted the lives of millions of people and have dramatically enhanced the ways that healthcare organizations do business and how people experience care.

As a medical student, Travis lived through the inefficiencies in healthcare IT firsthand. He eventually withdrew in his third year to found Bond Technologies, which built the first browser-based Electronic Medical Record (EMR) and successfully exited to MediNotes Corporation and Eclipsys (AllScripts). Through that exit, Travis held roles such as ESVP of Business Development and Chief Strategy Officer (CSO). He has since founded and led companies in spaces such as musculoskeletal care and chronic care management.

Travis holds a dual MBA from the UCLA Anderson School of Management and the National University Singapore (NUS), a BA in Chemistry from the University of South Florida, and a BS in Business Management from Florida International University - College of Business.

Antonella Santuccione Chadha
Antonella Santuccione Chadha, MD
Chief Medical Officer, Altoida

Dr. Antonella Santuccione Chadha is a medical doctor with expertise in clinical pathology, neuroscience and psychiatric disorders. She is Chief Medical Officer at Altoida, a commercial-stage technology company building the leading platform to accelerate and improve drug development, research, and care for people with neurological diseases using AI and multimodal data captured with a standard smartphone or tablet.

She is co-founder and CEO of the non-profit organization “Women’s Brain Project” which is addressing the influence of sex and gender on mental and brain diseases.

As a medical doctor, Antonella has decades of experience in preclinical research, patient treatment, clinical development, medical affairs and establishing international regulatory frameworks for Alzheimer’s disease (AD). She has worked with the Swiss Agency for therapeutic products, Roche Diagnostics and Roche Pharmaceutical, several European universities, the EU Commission Directorate for Health and Food Safety, the OECD, the CEOi, and several other Alzheimer’s’ disease organizations.

Since 2018, she has been listed among the top 100 Women in Business in Switzerland. In 2019, she was elected Woman of the Year in Switzerland by the Magazine "Women in Business.” In 2020, she received the World Sustainability Award for her involvement in advancing Precision Medicine. She also received the “Premio Medicina Italia” award for her contribution to the management of the global COVID-19 pandemic.

Optina Logo

Optina is leveraging hyperspectral imaging of the retina to detect an amyloid-beta signature in the eye. The team’s proprietary machine-learning approach extracts hundreds of unique spatial/spectral phenotypic features from data-rich retinal images, identifying subtle changes that may not be visible to the naked eye. With a first application in the early diagnosis of Alzheimer’s disease, Optina challenges the status quo by providing a diagnostic Retinal Deep Phenotyping platform to detect cerebral amyloid status. View screener.

David Lapointe
David Lapointe, MSc
President and Chief Executive Officer, Optina Diagnostics

David started his career in Sales and Marketing positions in the pharma and diagnostic industry. In 2001, he founded Advanced Molecular Imaging to bring molecular imaging technologies to the global pharma and research market. He then moved to Gamma Medica Ideas and became the VP of Marketing and Canadian Operation. He went on to hold the position of Global General Manager for Molecular Imaging and Research at GE Healthcare. At GE David was responsible for driving Global sales and product development of research diagnostics imaging. David co-founded and managed life science and IT companies in which he was responsible for driving strategic thinking and to accelerating growth against specific agendas.

David currently serves as CEO of Optina Diagnostics. Optina's Retinal Deep Phenotyping Platform, meant to diagnose Alzheimer's disease, offers non-invasive and more accessible testing. With an early and accurate diagnosis, physicians, patients, and caregivers will have better planning and early treatment options, making the patient journey much easier.

In his role, David has raised over $30M in financing to date and built a team of 40 employees, including data scientists, clinical specialists, and an experienced management team.

For any questions, please contact:
Sarah Giardina, PhD, Associate Director, Biomarker Development
sgiardina@alzdiscovery.org